Buy Recommendation for Inspire Medical Systems Driven by Efficiency and Growth Potential

Morgan Stanley analyst Kallum Titchmarsh has maintained their bullish stance on INSP stock, giving a Buy rating on June 12.

Kallum Titchmarsh’s rating is based on several compelling factors surrounding Inspire Medical Systems. The recent SLEEP 2025 meeting in Seattle highlighted the positive reception of the Inspire V device, which offers a better patient experience and significantly reduced procedure times for experienced centers. This efficiency is particularly attractive as it allows more procedures to be completed in a single day, enhancing the economic viability for surgeons.
Furthermore, feedback from medical professionals has been largely positive, with many noting the smooth rollout of Inspire V and its promising time savings. The initial data from Singapore also supports this, showing a notable reduction in implant times compared to the previous version, Inspire IV. Additionally, the potential for increased procedure volumes due to financial incentives in Ambulatory Surgery Centers (ASCs) further strengthens the case for a Buy rating. These factors collectively suggest a strong growth trajectory for Inspire Medical Systems, justifying the Buy recommendation.

In another report released on June 12, Jefferies also maintained a Buy rating on the stock with a $205.00 price target.

INSP’s price has also changed moderately for the past six months – from $188.830 to $129.710, which is a -31.31% drop .